Kinnate Biopharma Inc.

Equities

KNTE

US49705R1059

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-02 pm EDT			5-day change	1st Jan Change
2.650 ^USD	-0.38%		-.--%	+11.81%

Jun. 13	Kinnate Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 03	Kinnate Biopharma Inc. Announces Board Resignations	CI

Kinnate Biopharma Inc. Announces Workforce Restructuring

September 18, 2023 at 04:10 pm EDT

Kinnate Biopharma Inc. will implement a corporate restructuring by reducing the Company?s workforce by approximately 70%. The Company expects to have 28 remaining full-time employees. The Company is also taking related measures to reduce operating expenses.

This includes separating from all employees of its wholly-owned subsidiary in China, Kinnjiu Biopharma.

Latest news about Kinnate Biopharma Inc.

Kinnate Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Jun. 13	CI
Kinnate Biopharma Inc. Announces Board Resignations	Apr. 03	CI
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index	Apr. 02	CI
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..	Apr. 02	CI
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from S&P TMI Index	Apr. 02	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Kinnate Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
Kinnate Biopharma Sells Cancer Treatment Assets to Pierre Fabre Laboratories	Mar. 01	MT
Stifel Raises Kinnate Biopharma's Price Target to $2.59 From $1.50, Keeps Hold Rating	Feb. 26	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	Feb. 16	MT
Wedbush Adjusts Kinnate Biopharma's PT to $2.34 From $2 on Heels of Announced Sale Agreement With XOMA, Keeps Neutral Rating	Feb. 16	MT
XOMA Agrees to Acquire Kinnate Biopharma	Feb. 16	MT
XOMA Corporation entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. for approximately $120 million.	Feb. 15	CI
Kinnate Biopharma Plans to Further Reduce Workforce by 56%	Jan. 17	MT
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	Nov. 15	MT
Top Midday Gainers	Nov. 15	MT
Top Premarket Gainers	Nov. 15	MT
Kinnate Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
North American Morning Briefing : Fed Seen Holding -2-	23-09-20	DJ
Jefferies Cuts Price Target on Kinnate Biopharma to $2 From $31, Maintains Buy Rating	23-09-19	MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday	23-09-19	MT
Sector Update: Health Care	23-09-19	MT
HC Wainwright Downgrades Kinnate Biopharma to Neutral From Buy	23-09-19	MT

Chart Kinnate Biopharma Inc.

Duration

Period

More charts

Company Profile

Kinnate Biopharma Inc. is a clinical-stage precision oncology company. The Company is focused on the discovery, design, and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The Companyâs product candidate is KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor which was designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining, as well as other solid tumors. Its early-stage programs include a c-MET inhibitor that targets resistant variants and a brain penetrant CDK4 selective program. The Company concentrates its efforts on addressing known oncogenic drivers for targeted therapies and to overcome the limitations associated with existing cancer therapies, such as non-responsiveness or the development of acquired and intrinsic resistance.

Employees

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data